Table 2.
Plasma levels of VEGF, HE4 and CA125 in tested groups
|
Groups |
VEGF |
HE4 |
CA125 |
||
|---|---|---|---|---|---|
| (pg/ml) | (pmol/L) | (U/ml) | |||
|
Ovarian cancer Median Range |
stage I |
|
1/2 |
1/2 |
1 |
| |
166.18 |
83.50 |
63.50 |
||
| |
|
15.38 -656.56 |
28.60-1093.80 |
12.00-557.20 |
|
|
stage II |
|
1/2 |
1/2 |
1/2 |
|
| |
170.50 |
62.60 |
61.45 |
||
| |
|
8.92-2701.07 |
27.00-625.10 |
9.80-998.00 |
|
|
stage III |
|
1/2/4 |
1/2/4 |
1/2/4 |
|
| |
345.50 |
117.90 |
766.60 |
||
| |
|
10.70-1429.50 |
48.70-1500.00 |
10.10-2060.78 |
|
|
stage IV |
|
1/2/4/5 |
1/2/4 |
1/2/4 |
|
| |
143.50 |
198.00 |
531.90 |
||
| |
|
9.00-1386.00 |
37.80-1944.20 |
14.30-8602.30 |
|
|
Total group |
|
1/2 |
1/2 |
1/2 |
|
| |
168.48 |
103.60 |
133.30 |
||
| |
|
8.92-2701.07 |
27.00-1944.20 |
9.80-8602.30 |
|
|
Serous epithelial |
|
1/6 |
1/6/7/9 |
1/6/7 |
|
| |
166.18 |
126.00 |
171.21 |
||
| |
|
8.92-1429.50 |
28.60-1944.20 |
9.80-8602.30 |
|
|
Endometrioid epithelial |
|
1/6 |
1/6/7 |
1/6/7 |
|
| |
184.24 |
68.45 |
114.00 |
||
| |
|
|
9.00-2701.07 |
27.00-1740.00 |
11.10-1425.00 |
|
Control groups Median Range |
Benign ovarian tumor(Cystis) |
Endometrioides |
|
|
3/8 |
| 45.50 |
23.15 |
43.75 |
|||
| |
9.00-560.50 |
14.00-65.60 |
7.50-2748.00 |
||
|
Serous |
3 |
8 |
3 |
||
| 84.35 |
43.25 |
20.65 |
|||
| |
9.00-2100.00 |
26.80-156.40 |
5.80-451.80 |
||
|
Total group |
|
|
3 |
||
| 68.71 |
42.50 |
27.70 |
|||
| |
|
9.00-2100.00 |
14.00-156.40 |
5.80-2748.00 |
|
|
Healthy subjects |
39.31 |
44.15 |
9.94 |
||
| 2.30-467.10 | 6.20-122.30 | 5.06-36.60 | |||
1statistically significant when comparing OC patients with healthy subject.
2statistically significant when comparing OC patients with benign ovarian tumor total group.
3statistically significant when comparing patients with benign ovarian tumor and healthy subject.
4 statistically significant when comparing OC patients in stage III or IV with stage I or stage II.
5 statistically significant when comparing OC patients in stage IV with stage III.
6 statistically significant when comparing with benign ovarian tumor group. i.e. type cystis endometrioides.
7statistically significant when comparing with benign ovarian tumor group. i.e. type cystis serous.
8 statistically significant when comparing patients with benign ovarian tumor. i.e. type cystis endometrioides with type cystis serous.
9 statistically significant when comparing OC patients. i.e. sub-type serous epithelial with sub-type endometrioid epithelial.